Balyasny Asset Management
AKCA

Balyasny Asset Management’s Akcea Therapeutics Inc AKCA Stock Holding History

Balyasny Asset Management’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-8,647
Closed -$303K – 1915
2018
Q3 		$303K Buy
+8,647
New +$262K ﹤0.01% 1503

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balyasny Asset Management's AKCA Position: Q4 2018 in Review

Balyasny Asset Management sold out of Akcea Therapeutics Inc (AKCA) in Q4 2018, closing a stake of 8,647 shares — an estimated $303K sold.

Balyasny Asset Management first reported a position in AKCA in Q3 2018 and held it in 1 quarter. The position peaked at $303K in Q3 2018. 62 funds tracked by Wall St. Rank hold AKCA as of Q4 2018.

  • Balyasny Asset Management reported no remaining Akcea Therapeutics Inc position as of Q4 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 8,647 Akcea Therapeutics Inc shares in Q4 2018, an estimated $303K.
  • Balyasny Asset Management first reported a position in Akcea Therapeutics Inc in Q3 2018 and held it in 1 quarter.
  • Balyasny Asset Management's Akcea Therapeutics Inc position peaked at $303K in Q3 2018.
  • 62 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2018.

Based on Balyasny Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.